Three-year follow-up from CheckMate 017/057: Nivolumab versus docetaxel in patients with previously treated advanced non-small cell lung cancer (NSCLC)

被引：0
|
作者：
Felip Font, E. [1 ]
Gettinger, S. N. [2 ]
Burgio, M. A. [3 ]
Antonia, S. J. [4 ]
Holgado, E. [5 ]
Spigel, D. R. [6 ]
Arrieta, O. [7 ]
Domine Gomez, M. [8 ]
Aren Frontera, O. [9 ]
Brahmer, J. [10 ]
Chow, L. Q. [11 ]
Crino, L. [12 ]
Butts, C. [13 ]
Coudert, B. [14 ]
Horn, L. [15 ]
Steins, M. [16 ]
Geese, W. J. [17 ]
Li, A. [17 ]
Healey, D. [17 ]
Vokes, E. E. [18 ]
机构：
[1] Hosp Univ Vall dHebron, Thorac Tumors Grp, Barcelona, Spain
[2] Yale Canc Ctr, Oncol, New Haven, CT 06510 USA
[3] IRCCS Ist Sci Romagnolo Studio & Cura Tumori, Oncol, Meldola, Italy
[4] H Lee Moffitt Canc Ctr & Res Inst, Oncol, Tampa, FL USA
[5] Hosp Madrid, Oncol, Norte Sanchinarro, Madrid, Spain
[6] Tennessee Oncol PLLC, Sarah Cannon Res Inst, Med Oncol, Nashville, TN 37203 USA
[7] Inst Nacl Cancerol, Oncol, Mexico City, DF, Mexico
[8] Fdn Jimenez Diaz, Oncol, Madrid, Spain
[9] Ctr Int Estudios Clin, Oncol, Santiago, Chile
[10] Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Oncol, Baltimore, MD 21231 USA
[11] Univ Washington, Oncol, Seattle, WA 98195 USA
[12] Osped Perugia, Oncol, Perugia, Italy
[13] Cross Canc Inst, Oncol, Edmonton, AB, Canada
[14] Ctr Georges Francois Leclerc, Oncol, Dijon, France
[15] Vanderbilt Ingram Canc Ctr, Thorac Oncol, Nashville, TN 37232 USA
[16] Heidelberg Univ Hosp, Thoraxklin, Oncol, Heidelberg, Germany
[17] Bristol Myers Squibb, Immunooncol, Princeton, NJ 08540 USA
[18] Univ Chicago Med & Biol Sci, Oncol, Chicago, IL 60637 USA
来源：
ANNALS OF ONCOLOGY | 2017年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1301PD
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Analysis of Early Survival in Patients with Advanced Non-Squamous NSCLC Treated with Nivolumab vs Docetaxel in CheckMate 057
    Peters, Solange
    Cappuzzo, Frederico
    Horn, Leora
    Paz-Ares, Luis
    Borghaei, Hossein
    Barlesi, Fabrice
    Steins, Martin
    Felip, Enriqueta
    Spigel, David
    Dorange, Cecile
    Lu, Haolan
    Healey, Diane
    Sanchez, Teresa Kong
    Bhagavatheeswaran, Prabhu
    Novotny, James, Jr.
    Lestini, Brian
    Brahmer, Julie
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S253 - S253
  • [32] Efficacy and safety of sintilimab plus docetaxel in patients with previously treated advanced non-small cell lung cancer (NSCLC)
    Wang, Z.
    Han, X.
    Guo, J.
    Zhu, D.
    Zhang, X.
    Tang, X.
    Meng, X.
    ANNALS OF ONCOLOGY, 2020, 31 : S1400 - S1400
  • [33] CheckMate 017 and 057 studies of nivolumab vs docetaxel in patients with advanced NSCLC: 2-year-update and exploratory cytokine profile analyses
    Eberhardt, W. E. E.
    Borghaei, H.
    Brahmer, J. R.
    Horn, L.
    Ready, N.
    Steins, M.
    Felip, E.
    Paz-Ares, L. G.
    Arrieta, O.
    Barlesi, F.
    Antonia, S. J.
    Fayette, J.
    Rizvi, N. A.
    Crino, L.
    Reck, M.
    Hellmann, M.
    Desai, K.
    Li, A.
    Healey, D.
    Spigel, D. R.
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 33 - 33
  • [34] Comparative Effectiveness of Atezolizumab, Nivolumab, and Docetaxel in Patients With Previously Treated Non-Small Cell Lung Cancer
    Ramagopalan, Sreeram
    Gupta, Alind
    Arora, Paul
    Thorlund, Kristian
    Ray, Joshua
    Subbiah, Vivek
    JAMA NETWORK OPEN, 2021, 4 (11)
  • [35] Multicenter, randomized study of Docetaxel versus Docetaxel plus Oblimersen in patients previously treated for non-small cell lung cancer (NSCLC)
    Herbst, Roy S.
    Ansari, Rafat H.
    Gorbunova, V
    Manikhas, G.
    Mansoor, N. Boyd
    Thomas, E.
    Azzoli, Christopher G.
    Robert, Francisco
    Itri, Loretta M.
    Chapman, Robert
    JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (08) : S335 - S335
  • [36] HEALTH CARE RESOURCE UTILIZATION (HCRU) OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) TREATED WITH NIVOLUMAB VERSUS DOCETAXEL: RESULTS FROM THE CHECKMATE 078 (CM078) TRIAL
    Lawrance, R.
    DeRosa, M.
    Taylor, F.
    Penrod, J. R.
    Shaw, J. W.
    Wang, P. F.
    VALUE IN HEALTH, 2019, 22 : S79 - S79
  • [37] Second or Third Line Nivolumab Versus First Line Nivolumab in Patients with Previously Treated Advanced Non Small Cell Lung Cancer (NSCLC)
    Martinez Moreno, E.
    Irigoyen Medina, A.
    Alvarez Cabellos, R.
    Martinez, K. A.
    Santiago, J.
    Rivilla, M.
    Cardenas, J. D.
    Esteban, C.
    Trujillo, B.
    Rosero, A.
    Fernandez, L.
    Ramos, I.
    Ramos, A.
    Chacon, J. I.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S536 - S537
  • [38] LONGER-TERM FOLLOW-UP OF A PHASE 2 STUDY (CHECKMATE 063) OF NIVOLUMAB IN PATIENTS WITH ADVANCED REFRACTORY SQUAMOUS (SQ) NON-SMALL CELL LUNG CANCER (NSCLC)
    Horn, Leora
    Rizvi, Naiyer
    Mazieres, Julien
    Planchard, David
    Stinchcombe, Thomas E.
    Dy, Grace K.
    Antonia, Scott J.
    Lena, Herve
    Minenza, Elisa
    Mennecier, Bertrand
    Otterson, Gregory A.
    Campos, Luis T.
    Gandara, David R.
    Levy, Benjamin P.
    Nair, Suresh G.
    Zalman, Gerard
    Wolf, Juergen
    Paik, Paul
    Zhu, Jin
    Xu, Dong
    Neely, Jaclyn
    Qi, Zenhao
    Harbison, Christopher T.
    Lynch, Mark
    Ramalingam, Suresh S.
    Asia-Pacific Journal of Clinical Oncology, 2015, 11 : 124 - 124
  • [39] Impact of nivolumab versus docetaxel on disease-related symptoms in patients with advanced non-squamous NSCLC from CheckMate 057
    Horn, M.
    Gralla, R. J.
    Spigel, D. R.
    Bennett, B.
    Taylor, F.
    Penrod, J. R.
    DeRosa, M.
    Dastani, H.
    Orsini, Strycker L.
    Reck, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 103 - 103
  • [40] CheckMate 078: Patient-Reported Outcomes (PROs) With Nivolumab vs Docetaxel in Advanced Non-Small Cell Lung Cancer (NSCLC)
    Wu, Y.
    Chang, J.
    Zhang, L.
    Tu, H.
    Wu, L.
    Feng, J.
    Lu, S.
    Zhou, C.
    Wang, J.
    Mok, T.
    Taylor, F.
    Mossman, B.
    Penrod, J.
    Lawrance, R.
    Blum, S.
    Wang, P. F.
    Cheng, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (12) : S1047 - S1048
12345